Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00123669

Primary Progesterone Therapy for Operable Breast Cancer

The Primary Progesterone Therapy for Operable Breast Cancer : A Randomized Controlled Trial

Sponsor: Ministry of Science and Technology, India

Interventions 500 mg of depot hydroxy-progesterone

Updated 8 times since 2017 Last updated: Jul 21, 2020 Started: Oct 31, 1997 Primary completion: May 29, 2020 Completion: May 29, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Breast Neoplasms and is currently completed. Ministry of Science and Technology, India leads this study, which shows 8 recorded versions since 1997 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Aug 2020 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

Status: Active Not Recruiting → Completed
Apr 2020 — Aug 2020 [monthly]

Active Not Recruiting PHASE2_PHASE3

▶ Show 3 earlier versions

May 2019 — Apr 2020 [monthly]

Active Not Recruiting PHASE2_PHASE3
Jun 2018 — May 2019 [monthly]

Active Not Recruiting PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2_PHASE3

First recorded

Oct 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ministry of Science and Technology, India
Tata Memorial Hospital

Data source: Tata Memorial Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mumbai, India